Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Sequential Dose Escalation Clinical Study to Investigate the Safety, Tolerability and Pharmacokinetics of in Patients With Advanced Solid Tumor

NCT02151357 is registered in ClinicalTrials.gov with Standard Chem. & Pharm. Co., Ltd. as lead sponsor.

NCT NCT02151357
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02151357 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Sequential Dose Escalation Clinical Study to Investigate the Safety, Tolerability and Pharmacokinetics of in Patients With Advanced Solid Tumor
Lead sponsor
Standard Chem. & Pharm. Co., Ltd.
Phase
Phase 1
Overall status
Terminated
Start date
August 19, 2014
Completion date
October 31, 2016
Enrollment
17 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancer